Caris Life Sciences, Inc. $CAI Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its stake in Caris Life Sciences, Inc. (NASDAQ:CAI) by 57,052.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 685,826 shares of the company’s stock after buying an additional 684,626 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.24% of Caris Life Sciences worth $18,504,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Global Retirement Partners LLC increased its holdings in shares of Caris Life Sciences by 99,900.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after buying an additional 999 shares during the last quarter. Olistico Wealth LLC purchased a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $31,000. GF Fund Management CO. LTD. purchased a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $150,000. Courier Capital LLC purchased a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $231,000. Finally, ProShare Advisors LLC purchased a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $336,000.

Caris Life Sciences Stock Performance

Shares of CAI opened at $16.49 on Friday. The company has a quick ratio of 6.52, a current ratio of 7.05 and a debt-to-equity ratio of 0.64. Caris Life Sciences, Inc. has a fifty-two week low of $14.19 and a fifty-two week high of $42.50. The business’s 50-day simple moving average is $17.85. The firm has a market capitalization of $4.66 billion and a P/E ratio of -2.17.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CAI shares. BTIG Research dropped their price target on shares of Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Jefferies Financial Group started coverage on shares of Caris Life Sciences in a research note on Monday, April 13th. They set a “buy” rating and a $28.00 target price for the company. New Street Research started coverage on shares of Caris Life Sciences in a research note on Friday, May 8th. They set a “market perform” rating for the company. Finally, Weiss Ratings upgraded shares of Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Caris Life Sciences presently has an average rating of “Hold” and an average price target of $27.56.

Insider Buying and Selling at Caris Life Sciences

In related news, Director Jeff L. Vacirca purchased 31,050 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $16.15 per share, with a total value of $501,457.50. Following the completion of the acquisition, the director directly owned 49,671 shares in the company, valued at $802,186.65. This trade represents a 166.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 50.00% of the stock is currently owned by corporate insiders.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.